Biotech10 hours ago
Dijon Biotech Company Inventiva Raises 348 Million to Complete Its Phase III
Inventiva’s stock surged over 80% on news of phase III trial financing for lanifibranor, targeting NASH liver disease. The €94.1 million initial funding will support trials...